Matsuno K, Matsunaga K, Senda T, Mita S
Central Research Laboratories, Santen Pharmaceutical Co., Ltd., Osaka, Japan.
J Pharmacol Exp Ther. 1993 May;265(2):851-9.
The effects of sigma ligands on the central acetylcholine (ACh) systems in the rat frontal cortex were examined. By using brain microdialysis techniques, we showed that nonbenzomorphan sigma ligands, (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine and 1,3-di(2-tolyl)guanidine (DTG) dose-dependently increased the extracellular ACh level in this area. Similarly, benzomorphan sigma ligands, (+/-)-pentazocine and (+)-N-allylnormetazocine [(+)-SKF-10,047] also increased the extracellular ACh level. The increase in extracellular ACh level elicited by (+)-SKF-10,047 was greater than that by (-)-SKF-10,047. Moreover, the (+)-SKF-10,047- and DTG-induced increase in the extracellular ACh level were reduced significantly by simultaneous administration of haloperidol, a putative sigma receptor antagonist, whereas the (+)-SKF-10,047-induced increase was unaffected by (+/-)-3-(2- carboxypiperazin-4-yl)-propyl-1-phosphonic acid, a competitive N-methyl-D-aspartate receptor channel antagonist. On the other hand, none of the sigma ligands tested in this study had any effects on acetylcholinesterase or choline acetyltransferase activity and sodium-dependent high affinity choline uptake site in the rat frontal cortex. Ranking of potency for increasing extracellular ACh level was in the following order: (+/-)-pentazocine > (+)-SKF-10,047 > (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine > DTG. This order was positively correlated with the order of binding potency for the (+)-[3H]SKF-10,047 binding site in the rat frontal cortex, but was not correlated with binding to the [3H]DTG, [3H]quinuclidinyl benzylate and [3H]AF-DX116 ([3H]11-[(2-[(dimethylamino)methyl]-1-piperidinyl)acetyl]-5, 11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one) binding sites.(ABSTRACT TRUNCATED AT 250 WORDS)
研究了西格玛配体对大鼠额叶皮质中枢乙酰胆碱(ACh)系统的影响。通过使用脑微透析技术,我们发现非苯并吗啡烷西格玛配体,(+)-3-(3-羟基苯基)-N-(1-丙基)哌啶和1,3-二(2-甲苯基)胍(DTG)剂量依赖性地增加了该区域的细胞外ACh水平。同样,苯并吗啡烷西格玛配体,(+/-)-喷他佐辛和(+)-N-烯丙基去甲左啡诺[(+)-SKF-10,047]也增加了细胞外ACh水平。(+)-SKF-10,047引起的细胞外ACh水平升高大于(-)-SKF-10,047引起的升高。此外,同时给予假定的西格玛受体拮抗剂氟哌啶醇可显著降低(+)-SKF-10,047和DTG诱导的细胞外ACh水平升高,而(+)-SKF-10,047诱导的升高不受竞争性N-甲基-D-天冬氨酸受体通道拮抗剂(+/-)-3-(2-羧基哌嗪-4-基)-丙基-1-膦酸的影响。另一方面,本研究中测试的西格玛配体均对大鼠额叶皮质中的乙酰胆碱酯酶或胆碱乙酰转移酶活性以及钠依赖性高亲和力胆碱摄取位点没有任何影响。增加细胞外ACh水平的效力排序如下:(+/-)-喷他佐辛>(+)-SKF-10,047>(+)-3-(3-羟基苯基)-N-(1-丙基)哌啶>DTG。该顺序与大鼠额叶皮质中(+)-[3H]SKF-10,047结合位点的结合效力顺序呈正相关,但与与[3H]DTG、[3H]喹核醇基苯甲酸酯和[3H]AF-DX116([3H]11-[(2-[(二甲氨基)甲基]-1-哌啶基)乙酰]-5,11-二氢-6H-吡啶并[2,3-b][1,4]苯并二氮杂卓-6-酮)结合位点的结合无关。(摘要截断于250字)